Subscribe

Autobio Diagnostics Co., Ltd. (603658.SS)

CNY32.46 +0.59 (+1.85%)
CN SHH Healthcare Medical - Diagnostics & Research
Address No. 199, 15th Avenue 450016
Zhengzhou, CN
CEO Zeng Li Yang
Website autobio.com.cn
IPO 2016-09-02
ISIN CNE100002GC4

Explore sections of this company profile

Description

Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY32.46 +0.59 (+1.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.06
Float Shares
160.86M
Free Float %
28.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.95% +2.48% +0.06% -7.68% -8.34% -5.36% -14.14% -41.62% -62.21% +107.55% +107.55%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
32.46
DCF (Unlevered) 59.20 +82.4%
DCF (Levered) 36.45 +12.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.36
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Diagnostics & Research: +7.9%
    -5.5% Q1'26: -0.4% (vs Q1'25)
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    -9.7% Q1'26: -12.8% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +21.5% ★ Q1'26: +1.6% (vs Q1'25)
  • ✓
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +29.3% ★ Q1'26: +24.3% (vs Q1'25)
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    +12.3% ★ Q1'26: +9.6% (vs Q1'25)
  • ✓
    Share dilution Medical - Diagnostics & Research: 0.0%
    -1.0% ★ Q1'26: -0.5% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.59× Q1'26: 0.91× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.06) × ERP
WACC = 95% × Ke + 5% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 59.20 Current price: 32.46
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
7 Rev. Ana.
6 EPS Ana. 		Dec 2027
7 Rev. Ana.
7 EPS Ana. 		Dec 2028
4 Rev. Ana.
4 EPS Ana.
Revenue
980.22M
est: 926.50M (+5.8%)
1.40B
est: 1.40B (-0.1%)
1.93B
est: 1.91B (+1.1%)
2.68B
est: 2.67B (+0.3%)
2.98B
est: 3.03B (-1.8%)
3.77B
est: 3.77B (0.0%)
4.44B
est: 4.50B (-1.3%)
4.44B
est: 4.54B (-2.2%)
4.47B
est: 4.85B (-7.9%)
4.23B
est: 4.12B (+2.6%)
4.53B
4.29B – 4.62B
+9.8% YoY
5.05B
4.73B – 5.22B
+11.7% YoY
5.78B
5.77B – 5.80B
+14.4% YoY
EBITDA
462.48M
est: 333.15M (+38.8%)
602.42M
est: 504.04M (+19.5%)
794.92M
est: 686.22M (+15.8%)
1.08B
est: 960.65M (+12.7%)
1.08B
est: 1.09B (-0.8%)
1.34B
est: 1.35B (-1.0%)
1.54B
est: 1.62B (-4.6%)
1.64B
est: 2.05B (-20.0%)
1.62B
est: 2.19B (-26.3%)
1.70B
est: 1.86B (-8.6%)
2.04B
1.94B – 2.09B
+9.8% YoY
2.28B
2.14B – 2.36B
+11.7% YoY
2.61B
2.60B – 2.62B
+14.4% YoY
EBIT
388.91M
est: 240.56M (+61.7%)
483.10M
est: 363.95M (+32.7%)
629.91M
est: 495.49M (+27.1%)
865.01M
est: 693.65M (+24.7%)
780.48M
est: 787.22M (-0.9%)
954.28M
est: 977.88M (-2.4%)
1.13B
est: 1.17B (-3.6%)
1.21B
est: 1.51B (-19.9%)
1.15B
est: 1.61B (-28.4%)
1.24B
est: 1.37B (-9.5%)
1.50B
1.42B – 1.53B
+9.8% YoY
1.68B
1.57B – 1.73B
+11.7% YoY
1.92B
1.91B – 1.92B
+14.4% YoY
Net Income
349.76M
est: 395.05M (-11.5%)
446.56M
est: 471.98M (-5.4%)
562.57M
est: 607.36M (-7.4%)
774.16M
est: 775.11M (-0.1%)
747.79M
est: 841.88M (-11.2%)
973.66M
est: 957.87M (+1.6%)
1.17B
est: 1.20B (-2.3%)
1.22B
est: 1.29B (-5.7%)
1.19B
est: 1.30B (-8.4%)
1.07B
est: 1.03B (+3.2%)
1.14B
1.07B – 1.18B
+10.0% YoY
1.31B
1.16B – 1.42B
+15.1% YoY
1.52B
1.46B – 1.58B
+15.7% YoY
SGA
292.35M
est: 186.89M (+56.4%)
289.63M
est: 282.75M (+2.4%)
392.27M
est: 384.95M (+1.9%)
545.87M
est: 538.89M (+1.3%)
586.65M
est: 611.59M (-4.1%)
755.52M
est: 759.71M (-0.6%)
854.50M
est: 907.43M (-5.8%)
916.56M
est: 818.44M (+12.0%)
949.25M
est: 874.50M (+8.5%)
377.15M
est: 742.45M (-49.2%)
815.53M
772.54M – 831.67M
+9.8% YoY
910.67M
852.65M – 939.84M
+11.7% YoY
1.04B
1.04B – 1.04B
+14.4% YoY
EPS
0.68
est: 0.68 (-0.7%)
0.82
est: 0.82 (+0.3%)
1.03
est: 1.05 (-2.1%)
1.42
est: 1.34 (+5.7%)
1.34
est: 1.46 (-8.2%)
1.66
est: 1.66 (+0.0%)
2.00
est: 2.07 (-3.5%)
2.10
est: 2.25 (-6.7%)
2.07
est: 2.33 (-11.3%)
1.87
est: 1.85 (+1.1%)
2.00
1.88 – 2.06
+7.9% YoY
2.27
2.04 – 2.49
+13.8% YoY
2.68
2.56 – 2.76
+18.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-28 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-27 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-26 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-25 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-22 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-21 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-20 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-19 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-18 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-15 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-14 A- 4/5 4/5 4/5 5/5 3/5 2/5 3/5
2026-05-13 A 4/5 4/5 4/5 5/5 3/5 3/5 3/5
2026-05-12 A- 4/5 3/5 4/5 5/5 3/5 3/5 3/5
2026-05-11 A- 4/5 3/5 4/5 5/5 3/5 3/5 3/5
2026-05-08 A- 4/5 3/5 4/5 5/5 3/5 3/5 3/5
2026-05-07 A- 4/5 3/5 4/5 5/5 3/5 3/5 3/5
2026-05-06 A- 4/5 3/5 4/5 5/5 3/5 3/5 3/5
2026-04-30 A- 4/5 3/5 4/5 5/5 2/5 3/5 3/5
2026-04-29 A- 4/5 3/5 4/5 5/5 2/5 3/5 3/5
2026-04-28 A- 4/5 3/5 4/5 5/5 2/5 3/5 3/5
2026-04-27 A- 4/5 3/5 4/5 5/5 2/5 3/5 3/5
2026-04-24 A- 4/5 3/5 4/5 5/5 2/5 3/5 3/5
2026-04-23 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-22 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-21 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-20 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-17 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-16 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
608.74M
OE per share TTM
1.07
Owner's Yield
3.18%
Maintenance CapEx ratio
57.58%
Maint CapEx / Avg PPE
80.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 29 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS 0.04% 16.2K 0.65%
2 WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L 0.04% 19.2K 0.54%
3 Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR 0.01% 8.0K 0.15%
4 Franklin FTSE China UCITS ETF FLXC.L 0.00% 79.0K 0.19%
5 Dimensional - Emerging Markets Value ETF DFEV 0.00% 58.8K 0.46%
6 Schwab Emerging Markets Equity ETF SCHE 0.00% 304.9K 0.06%
7 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 172.0K 0.29%
8 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 48.8K 0.26%
9 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 21.6K 0.48%
10 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 138.6K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
214.2K
Shares Outstanding
571.42M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chao Jie Feng Chief Financial Officer, Deputy GM & Director — female
Guang Yu Fu Executive Deputy GM & Director — male
Rui Feng Zhang Executive Deputy GM & Director — male
Rui Kuan Fang Deputy GM & Secretary of the Board of Directors — male
Wei Liu Supervisor & Director of Administrative Center — female
Xue Wei Wu Deputy GM & Director — male
Zeng Li Yang GM & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research